CONSOLIDATED STATEMENTS OF CONTINGENTLY REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (loss)	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2020	76,201,000
Beginning balance at Dec. 31, 2020	$ 309,500
Contingently Redeemable Common Stock
Reclassification of contingently redeemable common stock in connection with initial public offering ("IPO") (in shares)	(76,201,000)
Reclassification of contingently redeemable common stock in connection with initial public offering ("IPO")	$ (309,500)
Ending balance (in shares) at Dec. 31, 2021	0
Ending balance at Dec. 31, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020		249,374,000
Beginning balance at Dec. 31, 2020	(284,730)	$ 2,494	$ 263,966	$ (551,190)	$ 0	$ 0
Total Stockholders’ Equity (Deficit)
Net income (loss)	(406,787)			(406,487)		(300)
Reclassification of contingently redeemable common stock in connection with IPO (in shares)		76,201,000
Reclassification of contingently redeemable common stock in connection with initial public offering ("IPO")	$ 309,500	$ 762	308,738
Issuance of common stock in connection with IPO, net of offering costs (in shares)	9,300,000	53,590,000
Issuance of common stock in connection with IPO, net of offering costs	$ 1,163,133	$ 536	1,162,597
Issuance of common stock under partner physician group equity agreements upon IPO (in shares)		11,672,000
Issuance of common stock under partner physician group equity agreements upon IPO	268,467	$ 117	268,350
Exercises and vesting of stock-based awards (in shares)		9,258,000
Exercises and vesting of stock-based awards	18,086	$ 92	17,994
Stock-based compensation expense	23,927		23,927
Ending balance (in shares) at Dec. 31, 2021		400,095,000
Ending balance at Dec. 31, 2021	1,091,596	$ 4,001	2,045,572	(957,677)	0	(300)
Total Stockholders’ Equity (Deficit)
Net income (loss)	(106,864)			(106,553)		(311)
Other comprehensive income (loss)	(5,560)				(5,560)
Exercises and vesting of stock-based awards (in shares)		11,923,000
Exercises and vesting of stock-based awards	33,887	$ 119	33,768
Vesting of restricted stock units (in shares)		404,000
Vesting of restricted stock units	0	$ 4	(4)
Shares withheld related to net share settlement (in shares)		(37,000)
Shares withheld related to net share settlement	(831)		(831)
Stock-based compensation expense	$ 28,381		28,381
Ending balance (in shares) at Dec. 31, 2022	412,385,000	412,385,000
Ending balance at Dec. 31, 2022	$ 1,040,609	$ 4,124	2,106,886	(1,064,230)	(5,560)	(611)
Total Stockholders’ Equity (Deficit)
Net income (loss)	(262,803)			(262,596)		(207)
Other comprehensive income (loss)	3,262				3,262
Exercises and vesting of stock-based awards (in shares)		2,786,000
Exercises and vesting of stock-based awards	13,714	$ 28	13,686
Vesting of restricted stock units (in shares)		899,000
Vesting of restricted stock units	0	$ 9	(9)
Shares withheld related to net share settlement (in shares)		(68,000)
Shares withheld related to net share settlement	$ (1,847)	$ (1)	(1,846)
Common stock repurchase (in shares)	(9,600,000)	(9,615,000)
Common stock repurchase	$ (201,409)	$ (96)	(201,313)
Stock-based compensation expense	$ 69,495		69,495
Ending balance (in shares) at Dec. 31, 2023	406,387,000	406,387,000
Ending balance at Dec. 31, 2023	$ 661,021	$ 4,064	$ 1,986,899	$ (1,326,826)	$ (2,298)	$ (818)